{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:16:27Z","timestamp":1790946987468,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.jconrel.2012.06.008","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T21:36:34Z","timestamp":1339709794000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection"],"prefix":"10.1016","volume":"162","author":[{"given":"Jill M.","family":"Steinbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen J.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Mark","family":"Saltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-009-9082-7","article-title":"Vaginal drug delivery systems for HIV prevention","volume":"11","author":"Rohan","year":"2009","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.jconrel.2012.06.008_bb0010","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jama.296.8.964","article-title":"Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States","volume":"296","author":"Xu","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jconrel.2012.06.008_bb0175","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2471\/BLT.07.046128","article-title":"An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection","volume":"86","author":"Looker","year":"2008","journal-title":"Bull. World Health Organ."},{"issue":"5","key":"10.1016\/j.jconrel.2012.06.008_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","article-title":"The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics","volume":"35","author":"Corey","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1574-695X.2006.00165.x","article-title":"A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes","volume":"49","author":"Macmillan","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"issue":"4","key":"10.1016\/j.jconrel.2012.06.008_bb0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0b013e32832c1881","article-title":"Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention","volume":"4","author":"Tobian","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2012.06.008_bb0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2012.06.008_bb0185","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0507-518b","article-title":"Will there be an HIV vaccine in the next 10 years?","volume":"13","year":"2007","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2012.06.008_bb0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1586\/erv.09.60","article-title":"New concepts in herpes simplex virus vaccine development: notes from the battlefield","volume":"8","author":"Dasgupta","year":"2009","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0190","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.05461-11","article-title":"Zinc acetate\/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge","volume":"56","author":"Fernandez-Romero","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jconrel.2012.06.008_bb0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/iai.11.3.476-480.1975","article-title":"Genital herpesvirus hominis infection in mice. I. Development of an experimental model","volume":"11","author":"Overall","year":"1975","journal-title":"Infect. Immun."},{"issue":"7072","key":"10.1016\/j.jconrel.2012.06.008_bb0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature04263","article-title":"An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection","volume":"439","author":"Palliser","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.chom.2008.12.003","article-title":"Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene","volume":"5","author":"Wu","year":"2009","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.jconrel.2012.06.008_bb0070","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1128\/JVI.77.8.4558-4565.2003","article-title":"Progesterone increases susceptibility and decreases immune responses to genital herpes infection","volume":"77","author":"Kaushic","year":"2003","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.jconrel.2012.06.008_bb0075","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/jnv.9.6.594.602","article-title":"Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites","volume":"9","author":"Parr","year":"2003","journal-title":"J. Neurovirol."},{"issue":"23","key":"10.1016\/j.jconrel.2012.06.008_bb0080","doi-asserted-by":"crossref","first-page":"14632","DOI":"10.1128\/JVI.79.23.14632-14639.2005","article-title":"The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies","volume":"79","author":"Yim","year":"2005","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.jconrel.2012.06.008_bb0085","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JVI.78.5.2530-2536.2004","article-title":"In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa","volume":"78","author":"Linehan","year":"2004","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.jconrel.2012.06.008_bb0090","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nmat2444","article-title":"Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA","volume":"8","author":"Woodrow","year":"2009","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/jvi.45.1.332-342.1983","article-title":"Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein","volume":"45","author":"Spang","year":"1983","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.jconrel.2012.06.008_bb0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jconrel.2011.02.002","article-title":"Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system","volume":"155","author":"Wu","year":"2011","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2012.06.008_bb0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ymthe.2006.04.001","article-title":"Engineering mucosal RNA interference in vivo","volume":"14","author":"Zhang","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2012.06.008_bb0195","doi-asserted-by":"crossref","unstructured":"L.A. Wheeler, R. Trifonova, V. Vrbanac, E. Basar, S. McKernan, Z. Xu, E. Seung, M. Deruaz, T. Dudek, J.I. Einarsson, L. Yang, T.M. Allen, A.D. Luster, A.M. Tager, D.M. Dykxhoorn, J. Lieberman, Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121(6) 2401\u20132412.","DOI":"10.1172\/JCI45876"},{"issue":"2","key":"10.1016\/j.jconrel.2012.06.008_bb0115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.mt.6300356","article-title":"Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors","volume":"16","author":"Conwell","year":"2008","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2012.06.008_bb0120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/jgm.933","article-title":"Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice","volume":"8","author":"Khazanov","year":"2006","journal-title":"J. Gene Med."},{"issue":"Suppl 1","key":"10.1016\/j.jconrel.2012.06.008_bb0200","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.antiviral.2010.09.006","article-title":"Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines","volume":"88","author":"Whaley","year":"2010","journal-title":"Antiviral research"},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2009.10.013","article-title":"Development of topical microbicides to prevent the sexual transmission of HIV","volume":"85","author":"Buckheit","year":"2010","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.jconrel.2012.06.008_bb0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(08)70254-8","article-title":"Vaginal microbicides and the prevention of HIV transmission","volume":"8","author":"Cutler","year":"2008","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2012.06.008_bb0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nri1848","article-title":"Microbicides and other topical strategies to prevent vaginal transmission of HIV","volume":"6","author":"Lederman","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.jconrel.2012.06.008_bb0145","first-page":"52","article-title":"Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants","volume":"3","author":"Eszterhas","year":"2011","journal-title":"Infect. Dis. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425240903338055","article-title":"Nanoparticle-based vaginal drug delivery systems for HIV prevention","volume":"7","author":"Mallipeddi","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jconrel.2012.06.008_bb0210","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","author":"Abdool Karim","year":"2010","journal-title":"Science (New York, N.Y 329 (5996)"},{"issue":"57","key":"10.1016\/j.jconrel.2012.06.008_bb0215","first-page":"124","article-title":"Optimizing siRNA delivery to the genital mucosa","volume":"11","author":"Katakowski","year":"2006","journal-title":"Discov Med"},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2012.06.008_bb0165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejps.2009.04.004","article-title":"Quantifying drug release from PLGA nanoparticulates","volume":"37","author":"Corrigan","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2012.06.008_bb0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-005-9042-6","article-title":"Effect of polymer blending on the release of ganciclovir from PLGA microspheres","volume":"23","author":"Duvvuri","year":"2006","journal-title":"Pharm. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365912005019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365912005019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:26:52Z","timestamp":1759159612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365912005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0168365912005019"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.008","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}